Molecular markers of chemotherapy in advanced colorectal cancer: Back to square one

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 1902-1903

  Sobrero, Alberto ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; METHOTREXATE; OXALIPLATIN; TEGAFUR; TUMOR MARKER; UFT; URIDINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; COLON MUCOSA; COLORECTAL CANCER; DRUG EFFICACY; DRUG POTENCY; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; MISMATCH REPAIR; ONCOGENE K RAS; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL;

EID: 67649535304     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.018     Document Type: Note

References (6)

1. Koopman M. Predictive and prognostic makers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer [this issue].
2. Koopman M. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer [this issue].
3. Duffy M.J. Tumor markers in colorectal cancer: European Group on Tumor Markers guidelines for clinical use. Eur J Cancer 43 (2007) 1348-1360
4. Sargent D.J. Confirmation of dMMR as a predictive marker for lack of benefit of FU based chemotherapy in stage II and III colon cancer. J Clin Oncol 26 suppl (2008) [abstr 4008]
5. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 10 (2008) 1626-1634 [Epub 2008 March 3]
6. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 359 17 (2008) 1757-1765